CAMP4 Therapeutics (NASDAQ:CAMP) Cut to Strong Sell at Zacks Research

Zacks Research lowered shares of CAMP4 Therapeutics (NASDAQ:CAMP) from a hold rating to a strong sell rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on CAMP. Leerink Partners boosted their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, April 2nd. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and an average target price of $8.36.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $3.71 on Wednesday. The stock’s 50-day moving average is $4.26 and its two-hundred day moving average is $4.56. CAMP4 Therapeutics has a 1 year low of $1.32 and a 1 year high of $7.75. The firm has a market cap of $192.66 million, a price-to-earnings ratio of -1.57 and a beta of 0.10.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The firm had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, research analysts predict that CAMP4 Therapeutics will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics in the 4th quarter valued at approximately $61,000. Jefferies Financial Group Inc. purchased a new position in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at approximately $86,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at approximately $115,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.